Aduro BioTech, Inc.
(NASDAQ : ADRO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.56%183.801.3%$480.23m
ARRYArray BioPharma Inc.
0.05%46.538.1%$426.77m
CELGCelgene Corporation
0.35%98.171.3%$407.46m
GILDGilead Sciences, Inc.
0.41%68.540.9%$395.13m
BIIBBiogen Inc.
0.45%234.951.3%$352.27m
ILMNIllumina, Inc.
1.41%356.913.5%$286.20m
REGNRegeneron Pharmaceuticals, Inc.
3.22%320.832.6%$240.90m
VRTXVertex Pharmaceuticals Incorporated
0.61%182.861.9%$218.03m
AAgilent Technologies, Inc.
0.22%72.811.6%$195.66m
EXASExact Sciences Corporation
-0.83%115.0324.1%$187.59m
ALXNAlexion Pharmaceuticals, Inc.
3.43%128.022.0%$184.09m
BMRNBioMarin Pharmaceutical Inc.
1.35%86.174.3%$129.56m
SRPTSarepta Therapeutics, Inc.
-2.84%130.5914.7%$109.18m
INCYIncyte Corporation
2.03%86.592.5%$108.60m
MRTXMirati Therapeutics Inc.
3.10%104.372.5%$101.45m

Company Profile

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.